Orion Pharma and Qilu partner on pembrolizumab biosimilar for Europe
Orion Pharma and Qilu Pharma Europe have entered a European commercialisation agreement for a proposed intravenous pembrolizumab biosimilar.
Orion receives exclusive rights to distribute, market and sell the product across Europe, while Qilu will retain responsibility for development and supply.
Qilu will receive a share of Orion's profits as well as development, regulatory and sales milestone payments under the agreement.
Field | Content |
Article Type | Deals |
Companies | Orion Pharma; Qilu Pharma Europe |
Deal Type | Exclusive European commercialisation agreement |
Key Asset | Intravenous pembrolizumab biosimilar |
Reference Product | Keytruda |
Therapy Area | Oncology |
Technology/Modality | Monoclonal antibody biosimilar |
Geography | Europe |
Commercial Rights | Orion receives exclusive rights to distribute, market and sell the biosimilar across Europe |
Development Responsibilities | Qilu Pharma Europe will develop the product |
Supply Responsibilities | Qilu Pharma Europe will supply the product |
Financial Terms | Profit share plus development, regulatory and sales milestone payments; amounts not disclosed |
What Happened | Orion Pharma and Qilu Pharma Europe entered an agreement covering European commercialisation of a proposed intravenous pembrolizumab biosimilar. |
Why It Matters | The agreement gives Orion access to a high-value oncology biosimilar opportunity while providing Qilu with an established European commercial partner. |
Strategic Rationale | Orion contributes European commercial infrastructure while Qilu retains development and manufacturing responsibilities for the biosimilar. |
Potential Impact | The partnership could increase future competition in the European pembrolizumab market if the biosimilar gains regulatory approval. |
Key Takeaway | Orion has secured exclusive European commercial rights to Qilu's proposed pembrolizumab biosimilar. |
What to Watch | Development progress, European regulatory filing and approval, launch timing and disclosure of additional commercial terms. |
Primary Source | Orion Pharma |
Relevant Date | 6 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commentaires